Figure 2 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors

Kaplan–Meier plots of (A) confirmed DOR and (B) PFS, as assessed by IRC in patients with TMB ≥13 mut/Mb per the enrollment assay. When using a TMB cutoff of ≥13 mut/Mb per the enrollment assay (n = 129), median DOR was NE, and median IRC-assessed PFS was 2.7 months (95% CI, 1.5–4.2). #, Remaining patients at the corresponding time point; +, a censoring event.